The estimation of utility weights in cost-utility analysis for mental disorders: A systematic review

PharmacoEconomics

Volumn 31, Issue 12, 2013, Pages 1131-1154

  Sonntag, Michael ^a   König, Hans Helmut ^a   Konnopka, Alexander ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADDICTION; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; AUSTRALIAN QUALITY OF LIFE INSTRUMENT; CAREGIVER QUALITY OF LIFE INSTRUMENT; CHILDREN HEALTH QUESTIONNAIRE; COST UTILITY ANALYSIS; DEMENTIA; DEPRESSION; HEALTH AND ACTIVITY LIMITATION INDEX; HUMAN; INSOMNIA; MENTAL DISEASE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; PSYCHOSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW;

COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; HEALTH CARE COSTS; HUMANS; LOGISTIC MODELS; MARKOV CHAINS; MENTAL DISORDERS; QUALITY-ADJUSTED LIFE YEARS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84890330701     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0107-9     Document Type: Review

References (398)

1. Drummond MF, Sculpher MF, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
2. Brazier J, Deverill M, Green C, Harper R, Booth A. A review of the use of health status measures in economic evaluation. Health Technol Assess. 1999;3(9):i-iv, 1-164.
3. Brazier J, Ratcliffe J, Salomon J, Tsuchiya A. Measuring and valuing health benefits for economic evaluation. Oxford: Oxford University Press; 2007.
4. Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11(2):215-25.
5. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276(14):1172-7.
6. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276(16):1339-41.
7. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276(15):1253-8.
8. Chisholm D, Healey A, Knapp M. QALYs and mental health care. Soc Psychiatry Psychiatr Epidemiol. 1997;32(1):68-75.
9. Flood C. Should "standard gamble" and "time trade off" utility measurement be used more in mental health research? J Ment Health Policy Econ. 2010;13(2):65-72.
10. König HH. Measuring preferences of psychiatric patients. Psychiatr Prax. 2004;31(3):118-27.
11. Mavranezouli I. A review and critique of studies reporting utility values for schizophrenia-related health states. Pharmacoeconomics. 2010;28(12):1109-21.
12. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
13. Gerhards SA, de Graaf LE, Jacobs LE, Severens JL, Huibers MJ, Arntz A, et al. Economic evaluation of online computerised cognitive-behavioural therapy without support for depression in primary care: randomised trial. Br J Psychiatry. 2010;196(4):310-8.
14. Joesch JM, Sherbourne CD, Sullivan G, Stein MB, Craske MG, Roy-Byrne P. Incremental benefits and cost of coordinated anxiety learning and management for anxiety treatment in primary care. Psychol Med. 2012;42(9):1937-48.
15. Jonkers CC, Lamers F, Evers SM, Bosma H, Metsemakers JF, Van Eijk JT. Economic evaluation of a minimal psychological intervention in chronically ill elderly patients with minor or mild to moderate depression: a randomized trial (the DELTA-study). Int J Technol Assess Health Care. 2009;25(4):497-504.
16. Patel A, McCrone P, Leese M, Amaddeo F, Tansella M, Kilian R, et al. Cost-effectiveness of adherence therapy versus health education for people with schizophrenia: randomised controlled trial in four European countries. Cost Eff Resour Alloc. 2013;11(1):12.
17. Pyne JM, Fortney JC, Tripathi SP, Maciejewski ML, Edlund MJ, Williams DK. Cost-effectiveness analysis of a rural telemedicine collaborative care intervention for depression. Arch Gen Psychiatry. 2010;67(8):812-21.
18. Perlis RH, Patrick A, Smoller JW, Wang PS. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology. 2009;34(10):2227-36.
19. Anton SF, Revicki DA. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone. Psychopharmacol Bull. 1995;31(2):9.
20. Ascher-Svanum H, Stensland MD, Peng X, Faries DE, Stauffer VL, Osuntokun OO, et al. Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. Curr Med Res Opin. 2011;27(1):115-22.
21. Ascher-Svanum H, Furiak NM, Lawson AH, Klein TM, Smolen LJ, Conley RR, et al. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States. J Med Econ. 2012;15(3):531-47.
22. Benedict A, Arellano J, De Cock E, Baird J. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland. J Affect Disord. 2010;120(1-3):94-104.
23. Campbell S, Norris S, Standfield L, Suebwongpat A. Screening for postnatal depression within the Well Child Tamariki Ora Framework. Health Services Assessment Collaboration Report. 2008;1(2).
24. Canadian Coordinating Office for Health Technology Assessment. A clinical and economic evaluation of selective serotonin reuptake inhibitors in major depression. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1997.
25. Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol. 1997;17(4):298-307.
26. Cottrell S, Tilden D, Robinson P, Bae J, Arellano J, Edgell E, et al. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. Value Health. 2008;11(3):376-88.
27. Damen J, Thuresson PO, Heeg B, Lothgren M. A pharmacoeconomic analysis of compliance gains on antipsychotic medications. Appl Health Econ Health Policy. 2008;6(4):189-97.
28. Ekman M, Lindgren P, Miltenburger C, Meier G, Locklear JC, Chatterton ML. Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode. Pharmacoeconomics. 2012;30(6):513-30.
29. Faber A, van Agthoven M, Kalverdijk LJ, Tobi H, de Jong-van den Berg LT, Annemans L, et al. Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands. CNS Drugs. 2008;22(2):157-70.
30. Furiak NM, Ascher-Svanum H, Klein RW, Smolen LJ, Lawson AH, Conley RR, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc. 2009;7:4.
31. Furiak NM, Ascher-Svanum H, Klein RW, Smolen LJ, Lawson AH, Montgomery W, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Current Med Res Opinion. 2011;27(4):17.
32. Graham CN, Mauskopf JA, Lawson AH, Ascher-Svanum H, Bruhn D. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia. Value Health. 2012;15(1):55-64.
33. Hong J, Dilla T, Arellano J. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain. BMC Psychiatry. 2009;9:15.
34. Kaltenthaler E, Shackley P, Stevens K, Beverley C, Parry G, Chilcott J. A systematic review and economic evaluation of computerised cognitive behaviour therapy for depression and anxiety. Health Technol Assess. 2002;6(22):1-89.
35. Kapoor A, Kraemer KL, Smith KJ, Roberts MS, Saitz R. Cost-effectiveness of screening for unhealthy alcohol use with % carbohydrate deficient transferrin: results from a literature-based decision analytic computer model. Alcohol Clin Exp Res. 2009;33(8):1440-9.
36. King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess. 2006;10(23):iii-iv, xiii-146.
37. Kirbach S, Simpson K, Nietert PJ, Mintzer J. A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease. Clin Drug Investig. 2008;28(5):291-303.
38. Leelahanaj T. The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disorder: Thai economic model. J Med Assoc Thai. 2010;93(Suppl 6):S43-50.
39. Leelahanaj T. Developing Thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder. J Med Assoc Thai. 2010;93(Suppl 6):S35-42.
40. Mavissakalian MR, Schmier JK, Flynn JA, Revicki DA. Cost effectiveness of acute imipramine therapy versus two imipramine maintenance treatment regimens for panic disorder. Pharmacoeconomics. 2000;18(4):383-91.
41. Nuijten MJ. Assessment of clinical guidelines for continuation treatment in major depression. Value Health. 2001;4(4):281-94.
42. Oh P, Lanctôt KL, Mittmann N, Iskedjian M, Einarson TR. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ. 2001;4:137-56.
43. Oh PI, Iskedjian M, Addis A, Lanctot K, Einarson TR. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. Can J Clin Pharmacol. Winter. 2001;8(4):199-206.
44. Paulden M, Palmer S, Hewitt C, Gilbody S. Screening for postnatal depression in primary care: cost effectiveness analysis. BMJ. 2009;339:b5203.
45. Prasad S, Arellano J, Steer C, Libretto SE. Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK. Int J Clin Pract. 2009;63(7):1031-40.
46. Revicki DA, Brown RE, Palmer W, Bakish D, Rosser WW, Anton SF, et al. Modelling the cost effectiveness of antidepressant treatment in primary care. Pharmacoeconomics. 1995;8(6):16.
47. Revicki DA, Brown RE, Keller MB, Gonzales J, Culpepper L, Hales RE. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry. 1997;58(2):11.
48. Sado M, Knapp M, Yamauchi K, Fujisawa D, So M, Nakagawa A, et al. Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan. Aust N Z J Psychiatry. 2009;43(6):539-47.
49. Serretti A, Olgiati P, Bajo E, Bigelli M, De Ronchi D. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. World J Biol Psychiatry. 2011;12(7):501-15.
50. Simon J, Pilling S, Burbeck R, Goldberg D. Treatment options in moderate and severe depression: decision analysis supporting a clinical guideline. Br J Psychiatry. 2006;189:494-501.
51. Simpson KN, Welch MJ, Kozel FA, Demitrack MA, Nahas Z. Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis. Adv Ther. 2009;26(3):346-68.
52. Treur M, Heeg B, Moller HJ, Schmeding A, van Hout B. A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss. BMC Health Serv Res. 2009;9:32.
53. Valenstein M, Vijan S, Zeber JE, Boehm K, Buttar A. The cost-utility of screening for depression in primary care. Ann Intern Med. 2001;134(5):345-60.
54. Wang PS, Ganz DA, Benner JS, Glynn RJ, Avorn J. Should clozapine continue to be restricted to third-line status for schizophrenia? A decision-analytic model. J Ment Health Policy Econ. 2004;7(2):77-85.
55. Wang PS, Patrick A, Avorn J, Azocar F, Ludman E, McCulloch J, et al. The costs and benefits of enhanced depression care to employers. Arch Gen Psychiatry. 2006;63(12):1345-53.
56. Aziz M, Mehringer AM, Mozurkewich E, Razik GN. Cost-utility of 2 maintenance treatments for older adults with depression who responded to a course of electroconvulsive therapy: results from a decision analytic model. Can J Psychiatry. 2005;50(7):389-97.
57. Einarson TR, Geitona M, Chaidemenos A, Karpouza V, Mougiakos T, Paterakis P, et al. Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece. Ann Gen Psychiatry. 2012;11(1):18.
58. Einarson TR, Pudas H, Zilbershtein R, Jensen R, Vicente C, Piwko C, et al. Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland. J Med Econ. 2013;16(9):1096-105.
59. Mehnert A, Nicholl D, Pudas H, Martin M, McGuire A. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. J Med Econ. 2012;15(5):844-61.
60. Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, et al. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents. Pharmacoeconomics. 2012;30(8):e1-15.
61. Sköldunger A, Johnell K, Winblad B, Wimo A. Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer's disease: a simulation study. Curr Alzheimer Res. 2013;10(2):207-16.
62. Cheema N, Frangou F, McCrone P. Cost-effectiveness of ethyl-eicosapentaenoic acid in the treatment of bipolar disorder. Ther Adv Psychopharmacol. 2013;3(2):73-81.
63. McIntyre RS, Cragin L, Sorensen S, Naci H, Baker T, Roussy JP. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. J Eval Clin Pract. 2010;16(4):744-55.
64. Soares-Weiser K, Bravo Vergel Y, Beynon S, Dunn G, Barbieri M, Duffy S, et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess. 2007;11(39):iii-iv, ix-206.
65. Lindner LM, Marasciulo AC, Farias MR, Grohs GE. Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System. Rev Saude Publica. 2009;43(Suppl 1):62-9.
66. Perlis RH, Ganz DA, Avorn J, Schneeweiss S, Glynn RJ, Smoller JW, et al. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol. 2005;25(5):427-34.
67. Wimo A, Mattson B, Krakau I, Eriksson T, Nelvig A, Karlsson G. Cost-utility analysis of group living in dementia care. Int J Technol Assess Health Care. 1995;11(1):16.
68. Armstrong EP, Skrepnek GH, Haim Erder M M. Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. Curr Med Res Opin. 2007;23(2):251-8.
69. Barbosa C, Taylor B, Godfrey C, Rehm J, Parrott S, Drummond C. Modelling lifetime QALYs and health care costs from different drinking patterns over time: a Markov model. Int J Methods Psychiatr Res. 2010;19(2):97-109.
70. Barton GR, Hodgekins J, Mugford M, Jones PB, Croudace T, Fowler D. Cognitive behaviour therapy for improving social recovery in psychosis: cost-effectiveness analysis. Schizophr Res. 2009;112(1-3):158-63.
71. Blankers M, Nabitz U, Smit F, Koeter MW, Schippers GM. Economic evaluation of internet-based interventions for harmful alcohol use alongside a pragmatic randomized controlled trial. J Med Internet Res. 2012;14(5):e134.
72. Bodden DH, Dirksen CD, Bogels SM, Nauta MH, De Haan E, Ringrose J, et al. Costs and cost-effectiveness of family CBT versus individual CBT in clinically anxious children. Clin Child Psychol Psychiatry. 2008;13(4):543-64.
73. Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol Assess. 2012;16(21):1-470.
74. Bosmans J, de Bruijne M, van Hout H, van Marwijk H, Beekman A, Bouter L, et al. Cost-effectiveness of a disease management program for major depression in elderly primary care patients. J Gen Intern Med. 2006;21(10):1020-6.
75. Bosmans JE, van Schaik DJ, Heymans MW, van Marwijk HW, van Hout HP, de Bruijne MC. Cost-effectiveness of interpersonal psychotherapy for elderly primary care patients with major depression. Int J Technol Assess Health Care. 2007 Fall;23(4):480-7.
76. Bosmans JE, Hermens ML, de Bruijne MC, van Hout HP, Terluin B, Bouter LM, et al. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression. J Affect Disord. 2008;111(1):106-12.
77. Bosmans JE, Schreuders B, van Marwijk HW, Smit JH, van Oppen P, van Tulder MW. Cost-effectiveness of problem-solving treatment in comparison with usual care for primary care patients with mental health problems: a randomized trial. BMC Fam Pract. 2012;13:98.
78. Bosmans JE, Dozeman E, van Marwijk HW, van Schaik DJ, Stek ML, Beekman AT, et al. Cost-effectiveness of a stepped care programme to prevent depression and anxiety in residents in homes for the older people: a randomised controlled trial. Int J Geriatr Psychiatry. Epub 13 June 2013.
79. Byford S, Knapp M, Greenshields J, Ukoumunne OC, Jones V, Thompson S, et al. Cost-effectiveness of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: a decision-making approach. Psychol Med. 2003;33(6):977-86.
80. Byford S, Barrett B, Roberts C, Wilkinson P, Dubicka B, Kelvin RG, et al. Cost-effectiveness of selective serotonin reuptake inhibitors and routine specialist care with and without cognitive behavioural therapy in adolescents with major depression. Br J Psychiatry. 2007;191:521-7.
81. Chalder M, Wiles NJ, Campbell J, Hollinghurst SP, Searle A, Haase AM, et al. A pragmatic randomised controlled trial to evaluate the cost-effectiveness of a physical activity intervention as a treatment for depression: the treating depression with physical activity (TREAD) trial. Health Technol Assess. 2012;16(10):1-164, iii-iv.
82. Charlesworth G, Shepstone L, Wilson E, Thalanany M, Mugford M, Poland F. Does befriending by trained lay workers improve psychological well-being and quality of life for carers of people with dementia, and at what cost? A randomised controlled trial. Health Technol Assess. 2008;12(4):iii, v-ix, 1-78.
83. Crawford MJ, Killaspy H, Barnes TR, Barrett B, Byford S, Clayton K, et al. Group art therapy as an adjunctive treatment for people with schizophrenia: a randomised controlled trial (MATISSE). Health Technol Assess. 2012;16(8):iii-iv, 1-76.
84. Davidson KM, Tyrer P, Norrie J, Palmer SJ, Tyrer H. Cognitive therapy v. usual treatment for borderline personality disorder: prospective 6-year follow-up. Br J Psychiatry. 2010;197(6):456-62.
85. Davies LM, Lewis S, Jones PB, Barnes TR, Gaughran F, Hayhurst K, et al. Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry. 2007;191:14-22.
86. Davies LM, Barnes TR, Jones PB, Lewis S, Gaughran F, Hayhurst K, et al. A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. Value Health. 2008;11(4):549-62.
87. De Ridder A, De Graeve D. Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach. Pharmacoeconomics. 2009;27(1):69-80.
88. De Salas-Cansado M, Olivares JM, Alvarez E, Carrasco JL, Barrueta A, Rejas J. Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain. Clinicoecon Outcomes Res. 2012;4:157-68.
89. Dijkgraaf MG, van der Zanden BP, de Borgie CA, Blanken P, van Ree JM, van den Brink W. Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. BMJ. 2005;330(7503):1297.
90. Drummond C, Coulton S, James D, Godfrey C, Parrott S, Baxter J, et al. Effectiveness and cost-effectiveness of a stepped care intervention for alcohol use disorders in primary care: pilot study. Br J Psychiatry. 2009;195(5):448-56.
91. Ekers D, Godfrey C, Gilbody S, Parrott S, Richards DA, Hammond D, et al. Cost utility of behavioural activation delivered by the non-specialist. Br J Psychiatry. 2011;199(6):510-1.
92. Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, et al. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison. Appl Health Econ Health Policy. 2012;10(6):381-95.
93. Furze G, Dumville JC, Miles JN, Irvine K, Thompson DR, Lewin RJ. "Prehabilitation" prior to CABG surgery improves physical functioning and depression. Int J Cardiol. 2009;132(1):51-8.
94. Gagnon M, Rive B, Hux M, Guilhaume C. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. Can J Psychiatry. 2007;52(8):519-26.
95. Gensichen J, Petersen JJ, Von Korff M, Heider D, Baron S, Konig J, et al. Cost-effectiveness of depression case management in small practices. Br J Psychiatry. 2013;202:441-6.
96. Getsios D, Blume S, Ishak KJ, Maclaine GD. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation. Pharmacoeconomics. 2010;28(5):411-27.
97. Getsios D, Blume S, Ishak KJ, Maclaine G, Hernandez L. An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom. Alzheimers Dement. 2012;8(1):22-30.
98. Goodyer IM, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, et al. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial. Health Technol Assess. 2008;12(14):iii-iv, ix-60.
99. Gusi N, Reyes MC, Gonzalez-Guerrero JL, Herrera E, Garcia JM. Cost-utility of a walking programme for moderately depressed, obese, or overweight elderly women in primary care: a randomised controlled trial. BMC Public Health. 2008;8:231.
100. Guthrie E, Moorey J, Margison F, Barker H, Palmer S, McGrath G, et al. Cost-effectiveness of brief psychodynamic-interpersonal therapy in high utilizers of psychiatric services. Arch Gen Psychiatry. 1999;56(6):519-26.
101. Hartz S, Getsios D, Tao S, Blume S, Maclaine G. Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation. BMC Neurol. 2012;12:2.
102. Hedman E, Andersson E, Ljotsson B, Andersson G, Ruck C, Lindefors N. Cost-effectiveness of Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: results from a randomized controlled trial. Behav Res Ther. 2011;49(11):729-36.
103. Hollinghurst S, Peters TJ, Kaur S, Wiles N, Lewis G, Kessler D. Cost-effectiveness of therapist-delivered online cognitive-behavioural therapy for depression: randomised controlled trial. Br J Psychiatry. 2010;197(4):297-304.
104. Jones RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging. 2004;21(9):607-20.
105. Jönsson L. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. Am J Geriatr Pharmacother. 2005;3(2):77-86.
106. Kaltenthaler E, Brazier J, De Nigris E, Tumur I, Ferriter M, Beverley C, et al. Computerised cognitive behaviour therapy for depression and anxiety update: a systematic review and economic evaluation. Health Technol Assess. 2006;10(33):iii, xi-xiv, 1-168.
107. Karow A, Reimer J, Konig HH, Heider D, Bock T, Huber C, et al. Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry. 2012;73(3):e402-8.
108. Kendrick T, Simons L, Mynors-Wallis L, Gray A, Lathlean J, Pickering R, et al. A trial of problem-solving by community mental health nurses for anxiety, depression and life difficulties among general practice patients. The CPN-GP study. Health Technol Assess. 2005;9(37):1-104, iii.
109. Kendrick T, Peveler R, Longworth L, Baldwin D, Moore M, Chatwin J, et al. Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: randomised controlled trial. Br J Psychiatry. 2006;188:337-45.
110. Kim BR, Lee TJ, Lee HJ, Park BH, Yang BM. Cost-effectiveness of sertindole among atypical antipsychotics in the treatment of schizophrenia in South Korea. Value Health Reg Issues. 2012;1(1):59-65.
111. Knapp M, Windmeijer F, Brown J, Kontodimas S, Tzivelekis S, Haro JM, et al. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study. Pharmacoeconomics. 2008;26(4):341-58.
112. König HH, Born A, Heider D, Matschinger H, Heinrich S, Riedel-Heller SG, et al. Cost-effectiveness of a primary care model for anxiety disorders. Br J Psychiatry. 2009;195(4):308-17.
113. Kuo YC, Lan CF, Chen LK, Lan VM. Dementia care costs and the patient's quality of life (QoL) in Taiwan: home versus institutional care services. Arch Gerontol Geriatr. 2010;51(2):159-63.
114. Lambert RA, Lorgelly P, Harvey I, Poland F. Cost-effectiveness analysis of an occupational therapy-led lifestyle approach and routine general practitioner's care for panic disorder. Soc Psychiatry Psychiatr Epidemiol. 2010;45(7):741-50.
115. Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess. 2006;10(17):iii-iv, ix-xi, 1-165.
116. Lindström E, Eberhard J, Fors BM, Hansen K, Sapin C. A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. Nord J Psychiatry. 2011;65(6):403-13.
117. Lopez-Bastida J, Hart W, Garcia-Perez L, Linertova R. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. J Alzheimers Dis. 2009;16(2):399-407.
118. Maniadakis N, Kourlaba G, Mougiakos T, Chatzimanolis I, Jonsson L. Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece. BMC Health Serv Res. 2013;13:173.
119. Mansdotter AM, Rydberg MK, Wallin E, Lindholm LA, Andreasson S. A cost-effectiveness analysis of alcohol prevention targeting licensed premises. Eur J Public Health. 2007;17(6):618-23.
120. Mencacci C, Di Sciascio G, Katz P, Ripellino C. Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy. Clinicoecon Outcomes Res. 2013;5:87-99.
121. Nordström G, Despiegel N, Marteau F, Danchenko N, Maman K. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden. J Med Econ. 2010;13(3):10.
122. Nordström G, Danchenko N, Despiegel N, Marteau F. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder. Value Health. 2012;15(2):231-9.
123. Nosyk B, Guh DP, Bansback NJ, Oviedo-Joekes E, Brissette S, Marsh DC, et al. Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. CMAJ. 2012;184(6):E317-28.
124. Palmer S, Davidson K, Tyrer P, Gumley A, Tata P, Norrie J, et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. J Pers Disord. 2006;20(5):466-81.
125. Peveler R, Kendrick T, Buxton M, Longworth L, Baldwin D, Moore M, et al. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Health Technol Assess. 2005;9(16):1-134, iii.
126. Polsky D, Glick HA, Yang J, Subramaniam GA, Poole SA, Woody GE. Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial. Addiction. 2010;105(9):1616-24.
127. Ramsberg J, Asseburg C, Henriksson M. Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS One. 2012;7(8):e42003.
128. Rive B, Aarsland D, Grishchenko M, Cochran J, Lamure M, Toumi M. Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway. Int J Geriatr Psychiatry. 2012;27(6):573-82.
129. Romeo R, Knapp M, Hellier J, Dewey M, Ballard C, Baldwin R, et al. Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. Br J Psychiatry. 2013;202:121-8.
130. Scott GW, Scott HM, O'Keeffe KM, Gander PH. Insomnia - treatment pathways, costs and quality of life. Cost Eff Resour Alloc. 2011;9:10.
131. Serrano-Blanco A, Pinto-Meza A, Suarez D, Penarrubia MT, Haro JM. Cost-utility of selective serotonin reuptake inhibitors for depression in primary care in Catalonia. Acta Psychiatr Scand Suppl. 2006;432:39-47.
132. Serrano-Blanco A, Suarez D, Pinto-Meza A, Penarrubia MT, Haro JM. Fluoxetine and imipramine: are there differences in cost-utility for depression in primary care? J Eval Clin Pract. 2009;15(1):195-203.
133. Shearer J, Shanahan M, Darke S, Rodgers C, van Beek I, McKetin R, et al. A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence. Drug Alcohol Rev. 2010;29(3):235-42.
134. Silva Miguel L, Silva Miguel N, Ines M. A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal. Cost Eff Resour Alloc. 2013;11(1):8.
135. Smith KJ, Baik SH, Reynolds CF 3rd, Rollman BL, Zhang Y. Cost-effectiveness of Medicare drug plans in schizophrenia and bipolar disorder. Am J Manag Care. 2013;19(2):e55-63.
136. Sobocki P, Ekman M, Agren H, Jonsson B, Rehnberg C. Model to assess the cost-effectiveness of new treatments for depression. Int J Technol Assess Health Care. 2006 Fall;22(4):469-77.
137. Sobocki P, Ekman M, Ovanfors A, Khandker R, Jonsson B. The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder. Int J Clin Pract. 2008;62(4):623-32.
138. Soeteman DI, Verheul R, Delimon J, Meerman AM, van den Eijnden E, Rossum BV, et al. Cost-effectiveness of psychotherapy for cluster B personality disorders. Br J Psychiatry. 2010;196(5):396-403.
139. Soeteman DI, Verheul R, Meerman AM, Ziegler U, Rossum BV, Delimon J, et al. Cost-effectiveness of psychotherapy for cluster C personality disorders: a decision-analytic model in the Netherlands. J Clin Psychiatry. 2011;72(1):51-9.
140. Solomon D, Adams J, Graves N. Economic evaluation of St. John's wort (Hypericum perforatum) for the treatment of mild to moderate depression. J Affect Disord. 2013;148(2-3):228-34.
141. Stant AD, TenVergert EM, Wunderink L, Nienhuis FJ, Wiersma D. Economic consequences of alternative medication strategies in first episode non-affective psychosis. Eur Psychiatry. 2007;22(6):347-53.
142. Stant AD, TenVergert EM, Kluiter H, Conradi HJ, Smit A, Ormel J. Cost-effectiveness of a psychoeducational relapse prevention program for depression in primary care. J Mental Health Policy Econ. 2009;12(4):9.
143. Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs. 2004;18(13):911-32.
144. Ukatt RT. Cost effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT). BMJ. 2005;331(7516):544.
145. Underwood M, Lamb SE, Eldridge S, Sheehan B, Slowther A, Spencer A, et al. Exercise for depression in care home residents: a randomised controlled trial with cost-effectiveness analysis (OPERA). Health Technol Assess. 2013;17(18):1-281.
146. van Asselt AD, Dirksen CD, Arntz A, Giesen-Bloo JH, van Dyck R, Spinhoven P, et al. Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v. transference-focused psychotherapy. Br J Psychiatry. 2008;192(6):450-7.
147. van Roijen LH, van Straten A, Al M, Rutten F, Donker M. Cost-utility of brief psychological treatment for depression and anxiety. Br J Psychiatry. 2006;188:323-9.
148. Vera-Llonch M, Dukes E, Rejas J, Sofrygin O, Mychaskiw M, Oster G. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective. Eur J Health Econ. 2010;11(1):35-44.
149. Warmerdam L, Smit F, van Straten A, Riper H, Cuijpers P. Cost-utility and cost-effectiveness of internet-based treatment for adults with depressive symptoms: randomized trial. J Med Internet Res. 2010;12(5):e53.
150. Wilson E, Thalanany M, Shepstone L, Charlesworth G, Poland F, Harvey I, et al. Befriending carers of people with dementia: a cost utility analysis. Int J Geriatr Psychiatry. 2009;24(6):610-23.
151. Wolfs CA, Dirksen CD, Kessels A, Severens JL, Verhey FR. Economic evaluation of an integrated diagnostic approach for psychogeriatric patients: results of a randomized controlled trial. Arch Gen Psychiatry. 2009;66(3):313-23.
152. Zhang Y, Kivipelto M, Solomon A, Wimo A. Cost-effectiveness of a health intervention program with risk reductions for getting demented: results of a Markov model in a Swedish/Finnish setting. J Alzheimers Dis. 2011;26(4):735-44.
153. Berghout CC, Zevalkink J, Hakkaart-van Roijen L. A cost-utility analysis of psychoanalysis versus psychoanalytic psychotherapy. Int J Technol Assess Health Care. 2010;26(1):3-10.
154. Calvert NW, Burch SP, Fu AZ, Reeves P, Thompson TR. The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder. J Manag Care Pharm. 2006;12(4):322-30.
155. Dietl M, Kornhuber J, Schoffski O, Grassel E. Cost-effectiveness model of a community-based service for dementia caregivers. Gesundheitswesen. 2010;72(2):99-105.
156. Fajutrao LMM, Paulsson B, Liu S, Locklear J. Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis. Clin Ther. 2009;31(1):12.
157. Francois C, Montgomery SA, Despiegel N, Aballea S, Roiz J, Auquier P. Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder. Int J Clin Pract. 2008;62(11):1693-702.
158. Hay JW, Katon WJ, Ell K, Lee PJ, Guterman JJ. Cost-effectiveness analysis of collaborative care management of major depression among low-income, predominantly Hispanics with diabetes. Value Health. 2012;15(2):249-54.
159. Kendrick T, Chatwin J, Dowrick C, Tylee A, Morriss R, Peveler R, et al. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study. Health Technol Assess. 2009;13(22):iii-iv, ix-xi, 1-159.
160. Knapp M, Romeo R, Mogg A, Eranti S, Pluck G, Purvis R, et al. Cost-effectiveness of transcranial magnetic stimulation vs. electroconvulsive therapy for severe depression: a multi-centre randomised controlled trial. J Affect Disord. 2008;109(3):273-85.
161. McLoughlin DM, Mogg A, Eranti S, Pluck G, Purvis R, Edwards D, et al. The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis. Health Technol Assess. 2007;11(24):1-54.
162. Morgan K, Dixon S, Mathers N, Thompson J, Tomeny M. Psychological treatment for insomnia in the regulation of long-term hypnotic drug use. Health Technol Assess. 2004;8(8):iii-iv, 1-68.
163. Morrell CJ, Warner R, Slade P, Dixon S, Walters S, Paley G, et al. Psychological interventions for postnatal depression: cluster randomised trial and economic evaluation. The PoNDER trial. Health Technol Assess. 2009;13(30):iii-iv, xi-xiii, 1-153.
164. Mukuria C, Brazier J, Barkham M, Connell J, Hardy G, Hutten R, et al. Cost-effectiveness of an improving access to psychological therapies service. Br J Psychiatry. 2013;202(3):220-7.
165. O'Keeffe KM, Gander PH, Scott WG, Scott HM. Insomnia treatment in New Zealand. N Z Med J. 2012;125(1349):46-59.
166. Pyne JM, Rost KM, Zhang M, Williams DK, Smith J, Fortney J. Cost-effectiveness of a primary care depression intervention. J Gen Intern Med. 2003;18(6):432-41.
167. Pyne JM, Smith J, Fortney J, Zhang M, Williams DK, Rost K. Cost-effectiveness of a primary care intervention for depressed females. J Affect Disord. 2003;74(1):23-32.
168. Pyne JM, Rost KM, Farahati F, Tripathi SP, Smith J, Williams DK, et al. One size fits some: the impact of patient treatment attitudes on the cost-effectiveness of a depression primary-care intervention. Psychol Med. 2005;35(6):839-54.
169. van Ravesteijn H, Grutters J, olde Hartman T, Lucassen P, Bor H, van Weel C, et al. Mindfulness-based cognitive therapy for patients with medically unexplained symptoms: a cost-effectiveness study. J Psychosom Res. 2013;74(3):197-205.
170. Walters D, Connor JP, Feeney GF, Young RM. The cost effectiveness of naltrexone added to cognitive-behavioral therapy in the treatment of alcohol dependence. J Addict Dis. 2009;28(2):137-44.
171. Woodward TC, Tafesse E, Quon P, Kim J, Lazarus A. Cost-effectiveness of quetiapine with lithium or divalproex for maintenance treatment of bipolar I disorder. J Med Econ. 2009;12(4):259-68.
172. Woodward TC, Tafesse E, Quon P, Lazarus A. Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder. Pharmacoeconomics. 2010;28(9):751-64.
173. Caro JJ, Salas M, Ward A, Getsios D, Mehnert A. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands. Dement Geriatr Cogn Disord. 2002;14(2):84-9.
174. Caro J, Salas M, Ward A, Getsios D, Migliaccio-Walle K, Garfield F. Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries. Drugs Aging. 2004;21(10):677-86.
175. Fuh JL, Wang SJ. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan. Int J Geriatr Psychiatry. 2008;23(1):73-8.
176. Getsios D, Caro JJ, Caro G, Ishak K. Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada. Neurology. 2001;57(6):972-8.
177. Green C, Picot J, Loveman E, Takeda A, Kirby J, Clegg A. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. Pharmacoeconomics. 2005;23(12):1271-82.
178. Happich M, Schweikert B, Muhlbacher A. Cost-effectiveness of galantamine in a german context. Psychiatr Prax. 2005;32(3):142-50.
179. Ikeda S, Yamada Y, Ikegami N. Economic evaluation of donepezil treatment for Alzheimer's disease in Japan. Dement Geriatr Cogn Disord. 2002;13(1):33-9.
180. Kasuya M, Meguro K. Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model. Arch Gerontol Geriatr. 2010;50(3):295-9.
181. Kozel FA, George MS, Simpson KN. Decision analysis of the cost-effectiveness of repetitive transcranial magnetic stimulation versus electroconvulsive therapy for treatment of nonpsychotic severe depression. CNS Spectr. 2004;9(6):476-82.
182. Kulasingam SL, Samsa GP, Zarin DA, Rutschmann OT, Patwardhan MB, McCrory DC, et al. When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimer's dementia? A decision analysis. Value Health. 2003;6(5):542-50.
183. Lachaine J, Beauchemin C, Legault M, Bineau S. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease. Can J Psychiatry. 2011;56(10):596-604.
184. Martikainen J, Valtonen H, Pirttila T. Potential cost-effectiveness of a family-based program in mild Alzheimer's disease patients. Eur J Health Econ. 2004;5(2):136-42.
185. McMahon PM, Araki SS, Neumann PJ, Harris GJ, Gazelle GS. Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer disease. Radiology. 2000;217(1):58-68.
186. McMahon PM, Araki SS, Sandberg EA, Neumann PJ, Gazelle GS. Cost-effectiveness of PET in the diagnosis of Alzheimer disease. Radiology. 2003;228(2):515-22.
187. Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology. 1999;52(6):1138-45.
188. Payne K, Davies LM, Noyce PR, Weiss MC. The value of the managed entry of new drugs: a case study of donepezil. Int J Technol Assess Health Care. 2003 Winter;19(1):114-28.
189. Pfeil AM, Kressig RW, Szucs TD. Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland. Swiss Med Wkly. 2012;142:w13676.
190. Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, et al. Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. Arch Gen Psychiatry. 2007;64(11):1259-68.
191. Suh GH. Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea. Value Health. 2009;12 Suppl 3:S49-54.
192. Teipel SJ, Ewers M, Reisig V, Schweikert B, Hampel H, Happich M. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 2007;257(6):330-6.
193. Touchon J, Lachaine J, Beauchemin C, Granghaud A, Rive B, Bineau S. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France. Eur J Health Econ. Epub 9 Aug 2013.
194. Ward A, Caro JJ, Getsios D, Ishak K, O'Brien J, Bullock R. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. Int J Geriatr Psychiatry. 2003;18(8):740-7.
195. Pitkala KH, Laurila JV, Strandberg TE, Kautiainen H, Sintonen H, Tilvis RS. Multicomponent geriatric intervention for elderly inpatients with delirium: effects on costs and health-related quality of life. J Gerontol A Biol Sci Med Sci. 2008;63(1):56-61.
196. Pohjolainen V, Rasanen P, Roine RP, Sintonen H, Wahlbeck K, Karlsson H. Cost-utility of treatment of bulimia nervosa. Int J Eat Disord. 2010;43(7):596-602.
197. Wang LY, Nichols LP, Austin SB. The economic effect of Planet Health on preventing bulimia nervosa. Arch Pediatr Adolesc Med. 2011;165(8):756-62.
198. Gournay K, Brooking J. The community psychiatric nurse in primary care: an economic analysis. J Adv Nurs. 1995;22(4):769-78.
199. Lintvedt OK, Griffiths KM, Eisemann M, Waterloo K. Evaluating the translation process of an Internet-based self-help intervention for prevention of depression: a cost-effectiveness analysis. J Med Internet Res. 2013;15(1):e18.
200. Wilkinson G, Croft-Jeffreys C, Krekorian H, McLees S, Falloon I. QALYs in psychiatric care? Psychiatr Bull. 1990;14:582-5.
201. Harris AH, Gospodarevskaya E, Ritter AJ. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics. 2005;23(1):77-91.
202. Cummins C, Stevens A, Kisely S. The use of olanzapine as a first and second choice treatment in schizophrenia. Birmingham: Development and Evaluation Service Department of Public Health and Epidemiology; 1998.
203. Gilmore A, Milne R. Methylphenidate in children with hyperactivity: review and cost-utility analysis. Pharmacoepidemiol Drug Saf. 2001;10(2):85-94.
204. Greenhalgh J, Knight C, Hind D, Beverley C, Walters S. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. Health Technol Assess. 2005;9(9):1-156, iii-iv.
205. Drummond MF, Mohide EA, Tew M, Streiner DL, Pringle DM, Gilbert JR. Economic evaluation of a support program for caregivers of demented elderly. Int J Technol Assess Health Care. 1991;7(2):10.
206. Narayan S, Hay J. Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD. Expert Rev Pharmacoecon Outcomes Res. 2004;4(6):625-34.
207. Botteman MF, Ozminkowski RJ, Wang S, Pashos CL, Schaefer K, Foley DJ. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model. CNS Drugs. 2007;21(4):319-34.
208. Brazier J, Tumur I, Holmes M, Ferriter M, Parry G, Dent-Brown K, et al. Psychological therapies including dialectical behaviour therapy for borderline personality disorder: a systematic review and preliminary economic evaluation. Health Technol Assess. 2006;10(35):iii, ix-xii, 1-117.
209. Domino ME, Burns BJ, Silva SG, Kratochvil CJ, Vitiello B, Reinecke MA, et al. Cost-effectiveness of treatments for adolescent depression: results from TADS. Am J Psychiatry. 2008;165(5):588-96.
210. Domino ME, Foster EM, Vitiello B, Kratochvil CJ, Burns BJ, Silva SG, et al. Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial. J Am Acad Child Adolesc Psychiatry. 2009;48(7):711-20.
211. Heeg B, Buskens E, Botteman M, Caleo S, Ingham M, Damen J, et al. The cost-effectiveness of atypicals in the UK. Value Health. 2008;11(7):1007-21.
212. Hensen M, Heeg B, Lothgren M, van Hout B. Cost effectiveness of long-acting risperidone in Sweden. Appl Health Econ Health Policy. 2010;8(5):327-41.
213. Järbrink K, Kreif N, Benedict A, Locklear J. Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin. 2009;25(3):709-16.
214. Katon WJ, Schoenbaum M, Fan MY, Callahan CM, Williams J Jr, Hunkeler E, et al. Cost-effectiveness of improving primary care treatment of late-life depression. Arch Gen Psychiatry. 2005;62(12):1313-20.
215. Katon W, Unutzer J, Fan MY, Williams JW Jr, Schoenbaum M, Lin EH, et al. Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression. Diabetes Care. 2006;29(2):265-70.
216. Katon W, Russo J, Sherbourne C, Stein MB, Craske M, Fan MY, et al. Incremental cost-effectiveness of a collaborative care intervention for panic disorder. Psychol Med. 2006;36(3):353-63.
217. Laux G, Heeg B, van Hout BA, Mehnert A. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics. 2005;23(Suppl 1):49-61.
218. Lave JR, Frank RG, Schulberg HC, Kamlet MS. Cost-effectiveness of treatments for major depression in primary care practice. Arch Gen Psychiatry. 1998;55(7):645-51.
219. Lenox-Smith A, Greenstreet L, Burslem K, Knight C. Cost effectiveness of venlafaxine compared with generic fluoxetine of generic amitriptyline in major depressive disorder in the UK. Clin Drug Investig. 2009;29(3):11.
220. Lynch FL, Hornbrook M, Clarke GN, Perrin N, Polen MR, O'Connor E, et al. Cost-effectiveness of an intervention to prevent depression in at-risk teens. Arch Gen Psychiatry. 2005;62(11):1241-8.
221. Lynch FL, Dickerson JF, Clarke G, Vitiello B, Porta G, Wagner KD, et al. Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings. Arch Gen Psychiatry. 2011;68(3):253-62.
222. McCrone P, Knapp M, Proudfoot J, Ryden C, Cavanagh K, Shapiro DA, et al. Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial. Br J Psychiatry. 2004;185:55-62.
223. Nagy B, Brennan A, Brandtmuller A, Thomas SK, Sullivan SD, Akehurst R. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models. Int J Geriatr Psychiatry. 2011;26(5):483-94.
224. Revicki DA, Siddique J, Frank L, Chung JY, Green BL, Krupnick J, et al. Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women. Arch Gen Psychiatry. 2005;62(8):868-75.
225. Rive B, Grishchenko M, Guilhaume-Goulant C, Katona C, Livingston G, Lamure M, et al. Cost effectiveness of memantine in Alzheimer's disease in the UK. J Med Econ. 2010;13(2):9.
226. Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163(12):2080-9.
227. Rost K, Pyne JM, Dickinson LM, LoSasso AT. Cost-effectiveness of enhancing primary care depression management on an ongoing basis. Ann Fam Med. 2005;3(1):7-14.
228. Sava FA, Yates BT, Lupu V, Szentagotai A, David D. Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating depression: a randomized clinical trial. J Clin Psychol. 2009;65(1):36-52.
229. Schoenbaum M, Unutzer J, Sherbourne C, Duan N, Rubenstein LV, Miranda J, et al. Cost-effectiveness of practice-initiated quality improvement for depression: results of a randomized controlled trial. JAMA. 2001;286(11):1325- 30.
230. Schoenbaum M, Miranda J, Sherbourne C, Duan N, Wells K. Cost-effectiveness of interventions for depressed Latinos. J Ment Health Policy Econ. 2004;7(2):69-76.
231. Snedecor SJ, Botteman MF, Bojke C, Schaefer K, Barry N, Pickard AS. Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia. Sleep. 2009;32(6):817-24.
232. Snedecor SJ, Botteman M, Schaefer K, Sarocco P, Barry N, Pickard AS. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder. J Mental Health Policy Econ. 2010;13(1):8.
233. Stevenson MD, Scope A, Sutcliffe PA, Booth A, Slade P, Parry G, et al. Group cognitive behavioural therapy for postnatal depression: a systematic review of clinical effectiveness, cost-effectiveness and value of information analyses. Health Technol Assess. 2010 14(44):1-107, iii-iv.
234. Tran BX, Ohinmaa A, Duong AT, Do NT, Nguyen LT, Mills S, et al. Cost-effectiveness of methadone maintenance treatment for HIV-positive drug users in Vietnam. AIDS Care. 2012;24(3):283-90.
235. Treur M, Baca E, Bobes J, Canas F, Salvador L, Gonzalez B, et al. The cost-effectiveness of paliperidone extended release in Spain. J Med Econ. 2012;15(Suppl 1):26-34.
236. Trivedi MH, Wan GJ, Mallick R, Chen J, Casciano R, Geissler EC, et al. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder. J Clin Psychopharmacol. 2004;24(5):497-506.
237. Wells KB, Schoenbaum M, Duan N, Miranda J, Tang L, Sherbourne C. Cost-effectiveness of quality improvement programs for patients with subthreshold depression or depressive disorder. Psychiatr Serv. 2007;58(10):1269-78.
238. Weycker D, Taneja C, Edelsberg J, Erder MH, Schmitt FA, Setyawan J, et al. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. Curr Med Res Opin. 2007;23(5):1187-97.
239. Wiley-Exley E, Domino ME, Maxwell J, Levkoff SE. Cost-effectiveness of integrated care for elderly depressed patients in the PRISM-E study. J Mental Health Policy Econ. 2009;12(4):8.
240. Lenert LA, Sturley AP, Rapaport MH, Chavez S, Mohr PE, Rupnow M. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res. 2004;71(1):155-65.
241. Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord. 1998;48(1):25-36.
242. Neumann PJ, Kuntz KM, Leon J, Araki SS, Hermann RC, Hsu MA, Weinstein MC. Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers. Med Care. 1999;37(1):27-32.
243. Neumann PJ, Sandberg EA, Araki SS, Kuntz KM, Feeny D, Weinstein MC. A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease. Med Decis Making. 2000;20(4):413-22.
244. Lenert LA, Sherbourne CD, Sugar C, Wells KB. Estimation of utilities for the effects of depression from the SF-12. Med Care. 2000;38(7):763-70.
245. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19(1):155-62.
246. NICE. Guide to the methods of technology appraisal. London; 2008.
247. Food and Drug Administration. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Rockville: Food and Drug Administration; 2009.
248. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5(1):1-30.
249. Arnold D, Girling A, Stevens A, Lilford R. Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis. BMJ. 2009;339:b2688.
250. Whitehurst DG, Bryan S. Another study showing that two preference-based measures of health-related quality of life (EQ-5D and SF-6D) are not interchangeable. But why should we expect them to be? Value Health. 2011;14(4):531-8.
251. Wille N, Badia X, Bonsel G, Burstrom K, Cavrini G, Devlin N, et al. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res. 2010;19(6):875-86.
252. McCrone P, Patel A, Knapp M, Schene A, Koeter M, Amaddeo F, et al. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. J Ment Health Policy Econ. 2009;12(1):27-31.
253. Lamers LM, Bouwmans CA, van Straten A, Donker MC, Hakkaart L. Comparison of EQ-5D and SF-6D utilities in mental health patients. Health Econ. 2006;15(11):1229-36.
254. Mann R, Gilbody S, Richards D. Putting the 'Q' in depression QALYs: a comparison of utility measurement using EQ-5D and SF-6D health related quality of life measures. Soc Psychiatry Psychiatr Epidemiol. 2009;44(7):569-78.
255. Longworth L, Rowen DL. NICE DSU Technical Support Document 10: the use of mapping methods to estimate health utility values. 2011.
256. Brazier J, Deverill M. A checklist for judging preference-based measures of health related quality of life: learning from psychometrics. Health Econ. 1999;8(1):41-51.
257. Knapp M, Mangalore R. The trouble with QALYs. Epidemiol Psichiatr Soc. 2007;16(4):289-93.
258. van de Willige G, Wiersma D, Nienhuis FJ, Jenner JA. Changes in quality of life in chronic psychiatric patients: a comparison between EuroQol (EQ-5D) and WHOQoL. Qual Life Res. 2005;14(2):441-51.
259. Versteegh MM, Leunis A, Uyl-de Groot CA, Stolk EA. Condition-specific preference-based measures: benefit or burden? Value Health. 2012;15(3):504-13.
260. Chuang LH, Whitehead SJ. Mapping for economic evaluation. Br Med Bull. 2012;101:1-15.
261. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095-108.
262. Dolan P, Gudex C, Kind P, Williams A. The time trade-off method: results from a general population study. Health Econ. 1996;5(2):141-54.
263. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271-92.
264. Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu Z, DePauw S, et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care. 2002;40(2):113-28.
265. Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care. 1996;34(7):702-22.
266. Torrance GW, Furlong W, Feeny D, Boyle M. Multi-attribute preference functions. Health utilities index. Pharmacoeconomics. 1995;7(6):503-20.
267. Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Serv Res. 1988;23(2):203-35.
268. Albon E, Tsourapas A, Frew E, Davenport C, Oyebode F, Bayliss S, et al. Structural neuroimaging in psychosis: a systematic review and economic evaluation. Health Technol Assess. 2008;12(18):iii-iv, ix-163.
269. Anderson L, Lewis G, Araya R, Elgie R, Harrison G, Proudfoot J, et al. Self-help books for depression: how can practitioners and patients make the right choice? Br J Gen Pract. 2005;55(514):387-92.
270. Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs. 2004;18(13):877-93.
271. Barnett PG. The cost-effectiveness of methadone maintenance as a health care intervention. Addiction. 1999;94(4):479-88.
272. Barrett B, Byford S, Knapp M. Evidence of cost-effective treatments for depression: a systematic review. J Affect Disord. 2005;84(1):1-13.
273. Basu A. Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues. Schizophr Res. 2004;71(2-3):445-62.
274. Boudreau R, Moulton K, Cunningham J. Self-directed cognitive behavioural therapy for adults with diagnosis of depression: systematic review of clinical effectiveness, cost-effectiveness, and guidelines. CADTH Technol Overv. 2010;1(4):e0125.
275. Brauer CA, Rosen AB, Greenberg D, Neumann PJ. Trends in the measurement of health utilities in published cost-utility analyses. Value Health. 2006;9(4):213-8.
276. Bridle C, Palmer S, Bagnall AM, Darba J, Duffy S, Sculpher M, et al. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. Health Technol Assess. 2004;8(19):iii-iv, 1-187.
277. Broadstock M, Brinson D, Weston A. The effectiveness of compulsory, residential treatment of chronic alcohol or drug addiction in non-offenders. HSAC Report. 2008;1(1).
278. Burns T, Knapp M, Catty J, Healey A, Henderson J, Watt H, et al. Home treatment for mental health problems: a systematic review. Health Technol Assess. 2001;5(15):1-139.
279. Cartwright WS. Cost-benefit analysis of drug treatment services: review of the literature. J Ment Health Policy Econ. 2000;3(1):11-26.
280. Christensen H, Pallister E, Smale S, Hickie IB, Calear AL. Community-based prevention programs for anxiety and depression in youth: a systematic review. J Prim Prev. 2010;31(3):139-70.
281. Churchill R, Hunot V, Corney R, Knapp M, McGuire H, Tylee A, et al. A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression. Health Technol Assess. 2001;5(35):1-173.
282. Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technol Assess. 2001;5(1):1-137.
283. Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, et al. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease: a systematic review. Int J Technol Assess Health Care. 2002 Summer;18(3):497-507.
284. Conner TM, Crismon ML, Still DJ. A critical review of selected pharmacoeconomic analyses of antidepressant therapy. Ann Pharmacother. 1999;33(3):364-72.
285. Cooke M, Chaboyer W, Hiratos MA. Music and its effect on anxiety in short waiting periods: a critical appraisal. J Clin Nurs. 2005;14(2):145-55.
286. Croom KF, Plosker GL. Escitalopram: a pharmacoeconomic review of its use in depression. Pharmacoeconomics. 2003;21(16):1185-209.
287. Croom KF, Plosker GL. Spotlight on the pharmacoeconomics of escitalopram in depression. CNS Drugs. 2004;18(7):469-73.
288. Crott R, Gilis P. Economic comparisons of the pharmacotherapy of depression: an overview. Acta Psychiatr Scand. 1998;97(4):241-52.
289. Daban C, Martinez-Aran A, Cruz N, Vieta E. Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review. J Affect Disord. 2008;110(1-2):1-15.
290. Davis R, Wilde MI. Sertraline. A pharmacoeconomic evaluation of its use in depression. Pharmacoeconomics. 1996;10(4):409-31.
291. Dean BB, Gerner D, Gerner RH. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin. 2004;20(2):139-54.
292. Donohue JM, Pincus HA. Reducing the societal burden of depression: a review of economic costs, quality of care and effects of treatment. Pharmacoeconomics. 2007;25(1):7-24.
293. Dündar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, et al. Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. Health Technol Assess. 2004;8(24):iii-x, 1-125.
294. Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol. 2004;19(5):305-10.
295. Engel SG, Adair CE, Las Hayas C, Abraham S. Health-related quality of life and eating disorders: a review and update. Int J Eat Disord. 2009;42(2):179-87.
296. Evers SM, Van Wijk AS, Ament AJ. Economic evaluation of mental health care interventions. A review. Health Econ. 1997;6(2):161-77.
297. Fenton C, Scott LJ. Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44.
298. Fleeman N, McLeod C, Bagust A, Beale S, Boland A, Dundar Y, et al. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. Health Technol Assess. 2010;14(3):1-157, iii.
299. Foster GR, Scott DA, Payne S. The use of CT scanning in dementia. A systematic review. Int J Technol Assess Health Care. 1999 Spring;15(2):406-23.
300. Foster RH, Goa KL. Risperidone. A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics. 1998;14(1):97-133.
301. Frasch K, Neumann NU. Economic aspects of psychotherapy management in psychosomatics and psychiatry. A systematic survey of the literature. Nervenarzt. 1999;70(5):387-90.
302. Garcia-Lizana F, Munoz-Mayorga I. Telemedicine for depression: a systematic review. Perspect Psychiatr Care. 2010;46(2):119-26.
303. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11(3):203-26.
304. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321(7273):1371-6.
305. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J. Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression. Cochrane Database Syst Rev. 2006(3):CD001851.
306. Gilbody SM, House AO, Sheldon TA. Outcome measures and needs assessment tools for schizophrenia and related disorders. Cochrane Database Syst Rev. 2003(1):CD003081.
307. Gilbody S, Bower P, Whitty P. Costs and consequences of enhanced primary care for depression: systematic review of randomised economic evaluations. Br J Psychiatry. 2006;189:297-308.
308. Gordon L, Graves N, Hawkes A, Eakin E. A review of the cost-effectiveness of face-to-face behavioural interventions for smoking, physical activity, diet and alcohol. Chronic Illn. 2007;3(2):101-29.
309. Griebsch I, Coast J, Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics. 2005;115(5):e600-14.
310. Griffiths KM, Christensen H. Internet-based mental health programs: a powerful tool in the rural medical kit. Aust J Rural Health. 2007;15(2):81-7.
311. Hamann J, Leucht S, Kissling W. Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems. Pharmacopsychiatry. 2003;36(1):18-26.
312. Hargreaves WA, Gibson PJ. Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review. CNS Drugs. 2005;19(5):393-410.
313. Höffler J, Trenckmann U, Graf von der Schulenburg JM. Health economics and evaluation of schizophrenic psychoses in Germany. Fortschr Neurol Psychiatr. 2000;68(Suppl 1):S7-12.
314. Holm KJ, Jarvis B, Foster RH. Mirtazapine. A pharmacoeconomic review of its use in depression. Pharmacoeconomics. 2000;17(5):515-34.
315. Höschl C, Svestka J. Escitalopram for the treatment of major depression and anxiety disorders. Expert Rev Neurother. 2008;8(4):537-52.
316. Hounsome N, Orrell M, Edwards RT. EQ-5D as a quality of life measure in people with dementia and their carers: evidence and key issues. Value Health. 2011;14(2):390-9.
317. Hulstaert F, Thiry N, Eyssen M, Vrijens F. Pharmaceutical and non-pharmaceutical interventions in Alzheimer's Disease, a rapid assessment. KCE reports. 2009;111c.
318. Huntley AL, Araya R, Salisbury C. Group psychological therapies for depression in the community: systematic review and meta-analysis. Br J Psychiatry. 2012;200(3):184-90.
319. Husereau D, Wolfson C, Shukla VK. Drug treatments for Alzheimer's disease: efficacy, outcome measurements and cost-effectiveness. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2001. Technology overview no. 4.
320. Hyde C, Peters J, Bond M, Rogers G, Hoyle M, Anderson R, et al. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model. Age Ageing. 2013;42(1):14-20.
321. Jepson R, Di Blasi Z, Wright K, Ter Riet G. Scoping review of the effectiveness of mental services. York: NHS Centre for Reviews and Dissemination; 2001.
322. Jönsson L. Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease. Pharmacoeconomics. 2003;21(14):1025-37.
323. Keating GM, Lyseng-Williamson KA. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation. Pharmacoeconomics. 2010;28(3):231-54.
324. Kirby J, Green C, Loveman E, Clegg A, Picot J, Takeda A, et al. A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease. Drugs Aging. 2006;23(3):227-40.
325. Kisely SR, Campbell LA, Preston NJ. Compulsory community and involuntary outpatient treatment for people with severe mental disorders. Cochrane Database Syst Rev. 2011(2):CD004408.
326. Konghom S, Verachai V, Srisurapanont M, Suwanmajo S, Ranuwattananon A, Kimsongneun N, et al. Treatment for inhalant dependence and abuse. Cochrane Database Syst Rev. 2010(12):CD007537.
327. König HH, Friemel S. Health economics of psychological diseases. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006;49(1):46-56.
328. Konnopka A, Leichsenring F, Leibing E, König HH. Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: a systematic review. J Affect Disord. 2009;114(1-3):14-31.
329. Kraemer KL. The cost-effectiveness and cost-benefit of screening and brief intervention for unhealthy alcohol use in medical settings. Subst Abus. 2007;28(3):67-77.
330. Lamb HM, Goa KL. Rivastigmine: a pharmacoeconomic review of its use in Alzheimer's disease. Pharmacoeconomics. 2001;19(3):303-18.
331. Landon TM, Barlow DH. Cognitive-behavioral treatment for panic disorder: current status. J Psychiatr Pract. 2004;10(4):211-26.
332. Laux G. Pharmacoeconomics of the new antidepressants and antipsychotics. Psychiatr Prax. 2003;30(Suppl 2):90-3.
333. Llorca PM, Fernandez JL. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. Int J Clin Pract. 2007;61(4):702-10.
334. Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess. 2006;10(1):iii-iv, ix-xi, 1-160.
335. Lumley J, Austin MP, Mitchell C. Intervening to reduce depression after birth: a systematic review of the randomized trials. Int J Technol Assess Health Care. 2004 Spring;20(2):128-44.
336. Lyseng-Williamson KA, Plosker GL. Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease. Pharmacoeconomics. 2002;20(13):919-42.
337. McCrone P. Health economic measures in schizophrenia research. Br J Psychiatry Suppl. 2007;50:s42-5.
338. McIntosh B, Clark M, Spry C. Benzodiazepines in older adults: a review of clinical effectiveness, cost-effectiveness, and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2011.
339. McKeage K. Memantine: a review of its use in moderate to severe Alzheimer's disease. CNS Drugs. 2009;23(10):881-97.
340. Mead N, Lester H, Chew-Graham C, Gask L, Bower P. Effects of befriending on depressive symptoms and distress: systematic review and meta-analysis. Br J Psychiatry. 2010;196(2):96-101.
341. Meads C, Burls A, Gold L, Jobanputra P. In-patient versus out-patient care for eating disorders. Birmingham: Development and Evaluation Service Department of Public Health and Epidemiology; 1999.
342. Morimoto T, Fukui T. Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals. J Epidemiol. 2002;12(2):160-78.
343. Mujoomdar M, Spry C. Naltrexone for the treatment of alcohol dependence: a review of the clinical and cost-effectiveness. Ottawa: Health Technology Inquiry Service; 2009.
344. Müller-Riemenschneider F, Rasch A, Bockelbrink A, Vauth C, Willich SN, Greiner W. Efficacy and effectiveness of smoking prevention programs. Köln: DIMDI; 2008.
345. Murdoch D, Keam SJ. Escitalopram: a review of its use in the management of major depressive disorder. Drugs. 2005;65(16):2379-404.
346. Ndegwa S, Cunningham J. Naltrexone in combination with acamprosate for the treatment of alcohol dependence: a review of the clinical and cost-effectiveness. Ottawa: Health Technology Inquiry Service; 2009.
347. Neumeyer-Gromen A, Lampert T, Stark K, Kallischnigg G. Disease management programs for depression: a systematic review and meta-analysis of randomized controlled trials. Med Care. 2004;42(12):1211-21.
348. Ohinmaa A, Chatterley P, Nguyen T, Jacobs P. Telehealth in substance abuse and addiction: review of the literature on smoking, alcohol, drug abuse and gambling. Ottawa: Institute of Health Economics; 2010.
349. Pirraglia PA, Rosen AB, Hermann RC, Olchanski NV, Neumann P. Cost-utility analysis studies of depression management: a systematic review. Am J Psychiatry. 2004;161(12):2155-62.
350. Plosker GL, Lyseng-Williamson KA. Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease. Pharmacoeconomics. 2005;23(2):193-206.
351. Pohar SL, Nkansah E. Cognitive behavioural therapy for post traumatic stress disorder: a review of the clinical and cost-effectiveness. Ottawa: Health Technology Inquiry Service; 2010.
352. Pouryamout L, Dams J, Wasem J, Dodel R, Neumann A. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses. Drugs. 2012;72(6):789-802.
353. Radlberger P, Zechmeister I, Tarquin M. Health economic evaluations in psychiatry of children and adolescents: a systematic review. Wien: Ludwig Boltzmann Institute for Health Technology Assessment; 2009.
354. Revicki DA. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophr Res. 1999;1(35 Suppl):S101-9.
355. Riemsma RP, Forbes CA, Glanville JM, Eastwood AJ, Kleijnen J. General health status measures for people with cognitive impairment: learning disability and acquired brain injury. Health Technol Assess. 2001;5(6):1-100.
356. Rizzo M, Creed F, Goldberg D, Meader N, Pilling S. A systematic review of non-pharmacological treatments for depression in people with chronic physical health problems. J Psychosom Res. 2011;71(1):18-27.
357. Robinson L, Hutchings D, Corner L, Beyer F, Dickinson H, Vanoli A, et al. A systematic literature review of the effectiveness of non-pharmacological interventions to prevent wandering in dementia and evaluation of the ethical implications and acceptability of their use. Health Technol Assess. 2006;10(26):iii, ix-108.
358. Rodgers M, Asaria M, Walker S, McMillan D, Lucock M, Harden M, et al. The clinical effectiveness and cost-effectiveness of low-intensity psychological interventions for the secondary prevention of relapse after depression: a systematic review. Health Technol Assess. 2012;16(28):1-130.
359. Romeo R, Byford S, Knapp M. Annotation: economic evaluations of child and adolescent mental health interventions: a systematic review. J Child Psychol Psychiatry. 2005;46(9):919-30.
360. Rosenberg R. Outcome measures of antidepressive therapy. Acta Psychiatr Scand Suppl. 2000;402:41-4.
361. Ruger JP, Emmons KM. Economic evaluations of smoking cessation and relapse prevention programs for pregnant women: a systematic review. Value Health. 2008;11(2):180-90.
362. Schlander M. Long-acting medications for the hyperkinetic disorders. A note on cost-effectiveness. Eur Child Adolesc Psychiatry. 2007;16(7):421-9.
363. Schlander M. The pharmaceutical economics of child psychiatric drug treatment. Curr Pharm Des. 2010;16(22):2443-61.
364. Schlander M, Trott GE, Schwarz O. The health economics of attention deficit hyperactivity disorder in Germany. Part 2: therapeutic options and their cost-effectiveness. Nervenarzt. 2010;81(3):301-14.
365. Shah A, Murthy S, Suh GK. Is mental health economics important in geriatric psychiatry in developing countries? Int J Geriatr Psychiatry. 2002;17(8):758-64.
366. Shearer J, Green C, Ritchie CW, Zajicek JP. Health state values for use in the economic evaluation of treatments for Alzheimer's disease. Drugs Aging. 2012;29(1):31-43.
367. Shukla VK, Otten N, Coyle D. Drug treatments for Alzheimer's disease. III. A review of pharmacoeconomic evaluations. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2000. Technology report no. 11.
368. Simoens S, Ludbrook A, Matheson C, Bond C. Pharmaco-economics of community maintenance for opiate dependence: a review of evidence and methodology. Drug Alcohol Depend. 2006;84(1):28-39.
369. Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychiatry. 2010;55(3):126-35.
370. Steffen S, Kosters M, Becker T, Puschner B. Discharge planning in mental health care: a systematic review of the recent literature. Acta Psychiatr Scand. 2009;120(1):1-9.
371. Thota AB, Sipe TA, Byard GJ, Zometa CS, Hahn RA, McKnight-Eily LR, et al. Collaborative care to improve the management of depressive disorders: a community guide systematic review and meta-analysis. Am J Prev Med. 2012;42(5):525-38.
372. Turner R. Quality of life: experience with sertraline. Int Clin Psychopharmacol. 1994;9(Suppl 3):27-31.
373. van Steenbergen-Weijenburg KM, van der Feltz-Cornelis CM, Horn EK, van Marwijk HW, Beekman AT, Rutten FF, et al. Cost-effectiveness of collaborative care for the treatment of major depressive disorder in primary care. A systematic review. BMC Health Serv Res. 2010;10:19.
374. Warner KE. Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage. Pharmacoeconomics. 1997;11(6):538-49.
375. Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs. 2003;17(5):343-62.
376. Wimo A. Clinical and economic outcomes - friend or foe? Int Psychogeriatr. 2007;19(3):497-507.
377. Armstrong EP, Malone DC, Erder MH. A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder. Curr Med Res Opin. 2008;24(4):1115-21.
378. Bolin K, Wilson K, Benhaddi H, de Nigris E, Marbaix S, Mork AC, et al. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation - results from four European countries. Eur J Public Health. 2009;19(6):650-4.
379. Davies A, Vardeva K, Loze JY, L'Italien GJ, Sennfalt K, Baardewijk M. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK. Curr Med Res Opin. 2008;24(11):3275-85.
380. François C, Sintonen H, Toumi M. Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact. JME. 2002;73(5):91-107.
381. Gustavsson A, Van Der Putt R, Jonsson L, McShane R. Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2009;24(10):1072-8.
382. Hoogveldt B, Rive B, Severens J, Maman K, Guilhaume C. Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands. Neuropsychiatr Dis Treat. 2011;7:313-7.
383. Mortimer D, Segal L. Economic evaluation of interventions for problem drinking and alcohol dependence: cost per QALY estimates. Alcohol Alcohol. 2005;40(6):549-55.
384. Rosenheck R, Cramer J, Allan E, Erdos J, Frisman LK, Xu W, et al. Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Arch Gen Psychiatry. 1999;56(6):565-72.
385. Salize HJ, Jacke C, Kief S, Franz M, Mann K. Treating alcoholism reduces financial burden on care-givers and increases quality-adjusted life years. Addiction. 2013;108(1):62-70.
386. Vanagas G, Padaiga Z, Bagdonas E. Cost-utility analysis of methadone maintenance treatment in Lithuania. Medicina (Kaunas). 2010;46(4):286-92.
387. van den Berg M, van Baal PH, Tariq L, Schuit AJ, de Wit GA, Hoogenveen RT. The cost-effectiveness of increasing alcohol taxes: a modelling study. BMC Med. 2008;6:36.
388. Adi Y, Juarez-Garcia A, Wang D, Jowett S, Frew E, Day E, et al. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. Health Technol Assess. 2007;11(6):iii-iv, 1-85.
389. Bagnall AM, Jones L, Ginnelly L, Lewis R, Glanville J, Gilbody S, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess. 2003;7(13):1-193.
390. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11(9):1-171, iii-iv.
391. Dretzke J, Frew E, Davenport C, Barlow J, Stewart-Brown S, Sandercock J, et al. The effectiveness and cost-effectiveness of parent training/education programmes for the treatment of conduct disorder, including oppositional defiant disorder, in children. Health Technol Assess. 2005;9(50):iii, ix-x, 1-233.
392. Hatziandreu EJ, Brown RE, Revicki DA, Turner R, Martindale J, Levine S, et al. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. Pharmacoeconomics. 1994;5(3):249-68.
393. Lynch FL, Striegel-Moore RH, Dickerson JF, Perrin N, Debar L, Wilson GT, et al. Cost-effectiveness of guided self-help treatment for recurrent binge eating. J Consult Clin Psychol. 2010;78(3):322-33.
394. Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Intern Med. 2012;27(6):669-76.
395. Stephen JH, Halpern CH, Barrios CJ, Balmuri U, Pisapia JM, Wolf JA, et al. Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: a threshold and cost-effectiveness analysis. Addiction. 2012;107(3):624-34.
396. Zhang M, Owen RR, Pope SK, Smith GR. Cost-effectiveness of clozapine monitoring after the first 6 months. Arch Gen Psychiatry. 1996;53(10):954-8.
397. Kasteng F, Eriksson J, Sennfalt K, Lindgren P. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2011;124(3):214-25.
398. Katon W, Russo J, Lin EH, Schmittdiel J, Ciechanowski P, Ludman E, et al. Cost-effectiveness of a multicondition collaborative care intervention: a randomized controlled trial. Arch Gen Psychiatry. 2012;69(5):506-14.